as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,453.6
Change
-25.2 (-1.7%)
Open
₹1,464.8
Prev. Close
₹1,478.8
Day High
₹1,479.0
Day Low
₹1,439.2
Volume Analysis
Traded
125,029
Delivered
56,412
Delivery %
45.12%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (35.0%)
Weaknesses (0)
No signal for this stock
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,515.14 | ₹1,497.07 | ₹1,475.34 | ₹1,457.27 | ₹1,435.54 | ₹1,417.47 | ₹1,395.74 |
| Fibonacci | ₹1,497.07 | ₹1,481.87 | ₹1,472.47 | ₹1,457.27 | ₹1,442.07 | ₹1,432.67 | ₹1,417.47 |
| Camarilla | ₹1,464.55 | ₹1,460.9 | ₹1,457.25 | ₹1,457.27 | ₹1,449.95 | ₹1,446.3 | ₹1,442.66 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+8.78%
1 Week
-7.97%
1 Month
-1.86%
3 Months
+13.54%
6 Months
+42.51%
1 Year
-7.14%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹329.09
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
12.85%
Net margin 24.64% × asset turnover 0.47x × equity multiplier 1.11x
Company Overview
Sector
Healthcare
Market Cap
₹16,142 Cr
P/E (TTM)
58.1
ROE
12.5%
Book Value
₹193.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 23 Sep 2026. Not investment advice.
TopFund Analysis
Concord Biotech Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 63/100. The strongest factor is Financial Strength (100/100), while Valuation (2/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (35.0%).
TopFund Score — Fundamentals Quality
63/100 — AverageData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 28.2%
- −Stock is trading at 7.86 times its book value
- −The company has delivered a poor sales growth of 11.3% over past five years.
- −Company has high debtors of 159 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
USFDA inspection at Unit II, Valthera ended September 18, 2026 with one minor procedural observation.
Pursuant to Regulation 30(6) read with Schedule III of the SEBI (LODR), Regulations, 2015, as amended from time ....
The officials of the Company will be attending an Investor Conference on 26th August 2026 as per the schedule and details in the file uploaded …
Transcript of Q1 - FY27 Earnings call held on August 03, 2026
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 195 | 262 | 241 | 319 | 216 | 310 | 244 | 430 | 204 | 247 | 278 | 326 | 257 |
| Expenses + | 123 | 147 | 135 | 187 | 135 | 176 | 146 | 241 | 143 | 159 | 179 | 208 | 175 |
| Operating Profit | 72 | 116 | 106 | 132 | 81 | 134 | 98 | 189 | 61 | 88 | 98 | 118 | 82 |
| OPM % | 37.0% | 44.0% | 44.0% | 41.0% | 38.0% | 43.0% | 40.0% | 44.0% | 30.0% | 36.0% | 35.0% | 36.0% | 32.0% |
| Other Income + | 13 | 8 | 11 | 11 | 12 | 10 | 17 | 9 | 15 | 16 | 7 | 15 | 14 |
| Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 13 | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 | 19 | 20 | 18 |
| Profit before tax | 71 | 110 | 103 | 129 | 80 | 130 | 101 | 184 | 59 | 86 | 86 | 114 | 78 |
| Tax % | 23.0% | 26.0% | 25.0% | 26.0% | 25.0% | 27.0% | 25.0% | 24.0% | 25.0% | 26.0% | 26.0% | 22.0% | 26.0% |
| Net Profit + | 54 | 81 | 78 | 95 | 60 | 96 | 76 | 140 | 44 | 63 | 64 | 88 | 58 |
| EPS in Rs | 5 | 8 | 7 | 9 | 6 | 9 | 7 | 13 | 4 | 6 | 6 | 8 | 6 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 512 | 616 | 713 | 853 | 1,017 | 1,200 | 1,055 | 1,108 |
| Expenses + | 308 | 289 | 443 | 509 | 585 | 694 | 687 | 721 |
| Operating Profit | 205 | 327 | 270 | 344 | 432 | 506 | 368 | 388 |
| OPM % | 40.0% | 53.0% | 38.0% | 40.0% | 42.0% | 42.0% | 35.0% | 35.0% |
| Other Income + | 32 | 14 | 23 | 37 | 37 | 44 | 52 | 52 |
| Interest | 1 | 1 | 6 | 5 | 3 | 1 | 1 | 0 |
| Depreciation | 21 | 28 | 50 | 54 | 54 | 54 | 74 | 75 |
| Profit before tax | 214 | 313 | 238 | 322 | 413 | 495 | 345 | 364 |
| Tax % | 21.0% | 25.0% | 26.0% | 25.0% | 25.0% | 25.0% | 25.0% | — |
| Net Profit + | 169 | 235 | 175 | 240 | 308 | 372 | 259 | 273 |
| EPS in Rs | 178 | 247 | 184 | 23 | 29 | 36 | 25 | 26 |
| Dividend Payout % | 22.0% | 0.0% | 3.0% | 30.0% | 30.0% | 25.0% | 30.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Reserves | 761 | 990 | 1,094 | 1,280 | 1,516 | 1,802 | 2,007 |
| Borrowings + | 52 | 86 | 62 | 32 | 10 | 3 | 2 |
| Other Liabilities + | 118 | 97 | 147 | 192 | 164 | 219 | 212 |
| Total Liabilities | 941 | 1,183 | 1,313 | 1,514 | 1,701 | 2,034 | 2,232 |
| Fixed Assets + | 240 | 546 | 573 | 593 | 575 | 795 | 789 |
| CWIP | 141 | 18 | 74 | 173 | 211 | 51 | 79 |
| Investments | 199 | 141 | 74 | 137 | 246 | 335 | 491 |
| Other Assets + | 361 | 477 | 592 | 611 | 668 | 854 | 873 |
| Total Assets | 941 | 1,183 | 1,313 | 1,514 | 1,701 | 2,034 | 2,232 |
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 155 | 167 | 207 | 246 | 265 | 245 | 267 |
| Cash from Investing Activity + | -114 | -195 | -112 | -158 | -155 | -160 | -143 |
| Cash from Financing Activity + | -43 | 31 | -100 | -85 | -99 | -99 | -113 |
| Net Cash Flow | -1 | 3 | -4 | 3 | 12 | -14 | 11 |
| CFO/OP | 100 | 74 | 99 | 92 | 85 | 70 | 100 |
| Free Cash Flow | -1 | -38 | 52 | 101 | 180 | 134 | 172 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 40.5% | 40.52% | 41.03% | 38.46% | 37.95% | 37.93% | 37.41% | 37.94% | 38.32% | 38.75% | 38.9% | 39.04% |
| Promoters | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% |
| FII | 7.3% | 7.0% | 6.49% | 7.11% | 8.1% | 8.33% | 9.35% | 9.1% | 8.03% | 7.58% | 7.79% | 7.53% |
| DII | 8.12% | 8.4% | 8.41% | 10.35% | 9.89% | 9.65% | 9.16% | 8.85% | 9.55% | 9.58% | 9.22% | 9.37% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Concord Biotech Limited (this stock) | 16,142 | 58.1 | 7.99 | 12.5% |
| Dr Agarwals Health Care L | 15,686 | 106.0 | 7.75 | 5.99% |
| Vijaya Diagnostic Cen Ltd | 15,590 | 83.2 | 16.28 | 18.3% |
| Alembic Pharma Ltd | 16,708 | 22.4 | 2.94 | 13.4% |
| Alivus Life Sciences Ltd | 16,820 | 47.8 | — | — |
| Syngene International Ltd | 15,287 | 51.6 | 3.16 | 7.78% |
| Marksans Pharma Limited | 15,269 | 29.6 | 5.05 | 15.2% |
Which Mutual Funds Hold Concord Biotech Limited?
Frequently Asked Questions about Concord Biotech Limited
Concord Biotech Limited (CONCORDBIO) closed at ₹1,453.6 on NSE on 25 September 2026, down 25.2 (1.7%) from the previous close.
Concord Biotech Limited trades on the NSE (National Stock Exchange of India) under the symbol CONCORDBIO.
Concord Biotech Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 58.1.
Concord Biotech Limited has a dividend yield of 0.49%.
Concord Biotech Limited's 52-week high is ₹1,675.0 and its 52-week low is ₹987.0.
Concord Biotech Limited has a market capitalisation of ₹16,142 crore.
Concord Biotech Limited has a TopFund Quality Score of 63/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Concord Biotech Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.